{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:51:39Z","timestamp":1767135099378,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd013245","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,12,12]],"date-time":"2020-12-12T00:00:00Z","timestamp":1607731200000}}],"reference-count":82,"publisher":"Wiley","issue":"12","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd013245.pub2","type":"journal-article","created":{"date-parts":[[2020,12,12]],"date-time":"2020-12-12T12:26:30Z","timestamp":1607775990000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer"],"prefix":"10.1002","volume":"2020","author":[{"given":"Niranjan J","family":"Sathianathen","sequence":"additional","affiliation":[{"name":"Department of Urology; University of Minnesota; Minneapolis Minnesota USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makinna C","family":"Oestreich","sequence":"additional","affiliation":[{"name":"University of Minnesota Medical School; University of Minnesota; Minneapolis Minnesota USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah Jane","family":"Brown","sequence":"additional","affiliation":[{"name":"Health Sciences Libraries; University of Minnesota; Minneapolis Minnesota USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shilpa","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology, Oncology and Transplatation; University of Minnesota; Minneapolis Minnesota USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Badrinath R","family":"Konety","sequence":"additional","affiliation":[{"name":"Department of Urology; University of Minnesota; Minneapolis Minnesota USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Dahm","sequence":"additional","affiliation":[{"name":"Urology Section; Minneapolis VA Health Care System; Minneapolis Minnesota USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Kunath","sequence":"additional","affiliation":[{"name":"Department of Urology; University Hospital Erlangen; Erlangen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,12,12]]},"reference":[{"issue":"Suppl 5","key":"10.1002\/14651858.CD013245.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"v269","DOI":"10.1093\/annonc\/mdx370","article-title":"Benefits of abiraterone acetate plus prednisone (AA1P) when added to androgen deprivation therapy (ADT) in LATITUDE on patient (Pt) reported outcomes (PRO)","volume":"28","author":"CHi","year":"2017","journal-title":"Annals of Oncology"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013245.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"5028","DOI":"10.1200\/JCO.2018.36.15_suppl.5028","article-title":"Subsequent treatment after abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-na\u00efve prostate cancer (NDx-HR mCNPC): detailed analyses from the phase 3 LATITUDE trial","volume":"36","author":"CHi","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD013245.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S1470-2045(17)30911-7","article-title":"Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial","volume":"19","author":"Chi","year":"2018","journal-title":"Lancet Oncology"},{"issue":"6","key":"10.1002\/14651858.CD013245.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s11523-019-00685-x","article-title":"Adjusting overall survival estimates for treatment switching in metastatic, castration-sensitive prostate cancer: results from the LATITUDE study","volume":"14","author":"Feyerabend","year":"2019","journal-title":"Target Oncology"},{"issue":"15","key":"10.1002\/14651858.CD013245.pub2-BIB0005|cit5","first-page":"5028","article-title":"Longer term preplanned efficacy and safety analysis of abiraterone acetate plus prednisone (AA plus P) in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) from the phase 3 LATITUDE trial","volume":"36","author":"Fizazi","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013245.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"TPS5097","DOI":"10.1200\/jco.2013.31.15_suppl.tps5097","article-title":"Randomized double-blind, comparative study of abiraterone acetate (AA) plus low-dose prednisone (P) plus androgen deprivation therapy (ADT) versus ADT alone in newly diagnosed, high-risk, metastatic hormone-naive prostate cancer (mHNPC)","volume":"31","author":"Fizazi","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013245.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"LBA3","DOI":"10.1200\/JCO.2017.35.18_suppl.LBA3","article-title":"LATITUDE: a phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer","volume":"35","author":"Fizazi","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD013245.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD013245.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncology"},{"issue":"6","key":"10.1002\/14651858.CD013245.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1200\/JCO.2018.36.6_suppl.182","article-title":"Abiraterone acetate (AA) plus prednisone (P) 5 mg QD in metastatic castration-naive prostate cancer (mCNPC): Detailed safety analyses from the LATITUDE phase 3 trial","volume":"36","author":"Fizazi","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"11","key":"10.1002\/14651858.CD013245.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/jjco\/hyy129","article-title":"Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study","volume":"48","author":"Fukasawa","year":"2018","journal-title":"Japanese Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD013245.pub2-BIB0012|cit12","first-page":"1012","article-title":"Efficacy and safety of abiraterone acetate (AA) and low-dose prednisone (P) in Japanese patients with newly diagnosed, metastatic, hormone-naive prostate cancer (mHNPC): Subgroup analysis of LATITUDE trial","volume":"36","author":"Fukasawa","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD013245.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/cncr.31847","article-title":"Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE","volume":"125","author":"Li","year":"2019","journal-title":"Cancer"},{"issue":"4","key":"10.1002\/14651858.CD013245.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/cncr.31847","article-title":"Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE","volume":"125","author":"Li","year":"2019","journal-title":"Cancer"},{"issue":"6 Suppl 1","key":"10.1002\/14651858.CD013245.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1200\/JCO.2018.36.6_suppl.201","article-title":"Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE","volume":"38","author":"Li","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD013245.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.eururo.2019.11.021","article-title":"Correlation of prostate-specific antigen kinetics with overall survival and radiological progression-free survival in metastatic castration-sensitive prostate cancer treated with abiraterone acetate plus prednisone or placebos added to androgen deprivation therapy: post hoc analysis of phase 3 LATITUDE study","volume":"77","author":"Matsubara","year":"2020","journal-title":"European Urology"},{"key":"10.1002\/14651858.CD013245.pub2-BIB0017|cit17","first-page":"271","article-title":"LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT plus abiraterone acetate and prednisone (AAP) or placebo (PBO)","volume":"28","author":"Matsubara","year":"2018","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD013245.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/j.jval.2018.04.317","article-title":"Benefit of abiraterone acetate plus prednisone (AA+P) added to androgen deprivation therapy (ADT) in patients with high-risk, newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC): post hoc analysis of EQ-5D-5L from the latitude study","volume":"21 Suppl 1","author":"Metin","year":"2018","journal-title":"Value in Health"},{"issue":"7","key":"10.1002\/14651858.CD013245.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1093\/jjco\/hyaa030","article-title":"Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study","volume":"50","author":"Suzuki","year":"2020","journal-title":"Japanese Journal of Clinical Oncology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013245.pub2-BIB0020|cit20","first-page":"27","article-title":"Final analysis of phase 3 LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT)","volume":"123","author":"Woo","year":"2019","journal-title":"BJU International"},{"key":"10.1002\/14651858.CD013245.pub2-BIB0021|cit21","unstructured":"ClinicalTrialsgov Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) ClinicalTrials.gov 2005"},{"issue":"6","key":"10.1002\/14651858.CD013245.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.eururo.2019.08.006","article-title":"Abiraterone in \"high-\" and \"low-risk\" metastatic hormone-sensitive prostate cancer","volume":"76","author":"Hoyle","year":"2019","journal-title":"European Urology"},{"issue":"18 Suppl","key":"10.1002\/14651858.CD013245.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"LBA5003","DOI":"10.1200\/JCO.2017.35.18_suppl.LBA5003","article-title":"Adding abiraterone for men with high-risk prostate cancer (PCa) starting longterm androgen deprivation therapy (ADT): survival results from STAMPEDE (NCT00268476)","volume":"35","author":"James","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD013245.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD013245.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.urolonc.2017.12.009","article-title":"Metastatic burden in newly diagnosed hormone-naive metastatic prostate cancer: comparing definitions of CHAARTED and LATITUDE trial","volume":"36","author":"Buelens","year":"2018","journal-title":"Urologic Oncology: Seminars and Original Investigations"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD013245.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1200\/JCO.2018.36.6_suppl.200","article-title":"Indirect treatment comparison (ITC) of abiraterone acetate (AA) plus prednisone (P) and docetaxel (DOC) on patient-reported outcomes (PROs) in metastatic castration-naive prostate cancer (mCNPC)","volume":"36","author":"Feyerabend","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD013245.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"v619","DOI":"10.1093\/annonc\/mdx440.024","article-title":"Adding abiraterone acetate plus prednisolone (AAP) or docetaxel for patients (pts) with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Directly randomised data from STAMPEDE (NCT00268476)","volume":"28","author":"Sydes","year":"2017","journal-title":"Annals of Oncology"},{"issue":"5","key":"10.1002\/14651858.CD013245.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/annonc\/mdy072","article-title":"Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol","volume":"29","author":"Sydes","year":"2018","journal-title":"Annals of Oncology"},{"issue":"28","key":"10.1002\/14651858.CD013245.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1200\/JCO.2007.15.9749","article-title":"Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven","volume":"26","author":"Attard","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD013245.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD013245.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/sj.bjc.6602767","article-title":"Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease","volume":"93","author":"Berruti","year":"2005","journal-title":"British Journal of Cancer"},{"issue":"1","key":"10.1002\/14651858.CD013245.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1524-4733.2008.00409.x","article-title":"Estimating clinically meaningful changes for the functional assessment of cancer therapy \u2013 prostate: results from a clinical trial of patients with metastatic hormone-refractory prostate cancer","volume":"12","author":"Cella","year":"2009","journal-title":"Value in Health"},{"key":"10.1002\/14651858.CD013245.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013245.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"New England Journal of Medicine"},{"issue":"9747","key":"10.1002\/14651858.CD013245.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"Bono","year":"2010","journal-title":"Lancet"},{"issue":"21","key":"10.1002\/14651858.CD013245.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"Bono","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013245.pub2-BIB0037|cit37","unstructured":"Deeks JJ Higgins JP Altman DG Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/cochrane-handbook"},{"key":"10.1002\/14651858.CD013245.pub2-BIB0038|cit38","unstructured":"EndNote Clarivate Analytics 2016"},{"issue":"10","key":"10.1002\/14651858.CD013245.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","article-title":"Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study","volume":"13","author":"Fizazi","year":"2012","journal-title":"Lancet Oncology"},{"issue":"8","key":"10.1002\/14651858.CD013245.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/annonc\/mdv257","article-title":"Management of patients with advance prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015","volume":"26","author":"Gillessen","year":"2015","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD013245.pub2-BIB0041|cit41","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime)"},{"issue":"7651","key":"10.1002\/14651858.CD013245.pub2-BIB0042|cit42","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1136\/bmj.39490.551019.BE","article-title":"What is \"quality of evidence\" and why is it important to clinicians?","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"4","key":"10.1002\/14651858.CD013245.pub2-BIB0043|cit43","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction \u2013 GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"15","key":"10.1002\/14651858.CD013245.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1056\/NEJMoa1606220","article-title":"10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer","volume":"375","author":"Hamdy","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD013245.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1210\/er.2002-0032","article-title":"Androgen receptor in prostate cancer","volume":"25","author":"Heinlein","year":"2004","journal-title":"Endocrine Reviews"},{"issue":"11","key":"10.1002\/14651858.CD013245.pub2-BIB0046|cit46","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"7414","key":"10.1002\/14651858.CD013245.pub2-BIB0047|cit47","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD013245.pub2-BIB0048|cit48","unstructured":"Higgins JP Green S Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/cochrane-handbook"},{"key":"10.1002\/14651858.CD013245.pub2-BIB0049|cit49","unstructured":"Higgins JP Altman DG Sterne JA Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/cochrane-handbook"},{"issue":"2","key":"10.1002\/14651858.CD013245.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1001\/archsurg.1941.01210140043004","article-title":"Studies on prostatic cancer: Ii. the effects of castration on advanced carcinoma of the prostate gland","volume":"43","author":"Huggins","year":"1941","journal-title":"Archives of Surgery"},{"issue":"5","key":"10.1002\/14651858.CD013245.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.urology.2008.07.062","article-title":"Prevalence of skeletal complications and their impact on survival of hormone refractory prostate cancer patients in Japan","volume":"73","author":"Inoue","year":"2009","journal-title":"Urology"},{"issue":"6","key":"10.1002\/14651858.CD013245.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.eururo.2014.09.032","article-title":"Survival with newly diagnosed metastatic prostate cancer in the \u201cDocetaxel Era\u201d: data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK\/06\/019)","volume":"67","author":"James","year":"2015","journal-title":"European Urology"},{"key":"10.1002\/14651858.CD013245.pub2-BIB0053|cit53","unstructured":"James ND Sydes MR Clarke NW Mason MD Dearnaley DP Spears MR Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial Lancet 2016 387 10024 1163 77"},{"issue":"3","key":"10.1002\/14651858.CD013245.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0090-4295(96)00496-7","article-title":"Combined hormono\/chemotherapy as primary treatment for metastatic prostate cancer: a randomized, multicenter study of orchiectomy alone versus orchiectomy plus estramustine phosphate. The Dutch Estracyt Study Group","volume":"49","author":"Janknegt","year":"1997","journal-title":"Urology"},{"issue":"5","key":"10.1002\/14651858.CD013245.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD013245.pub2-BIB0056|cit56","doi-asserted-by":"publisher","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Medicine"},{"issue":"36","key":"10.1002\/14651858.CD013245.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"5936","DOI":"10.1200\/JCO.2007.15.9830","article-title":"Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer","volume":"26","author":"Millikan","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"7","key":"10.1002\/14651858.CD013245.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/1097-0142(19830401)51:7<1264::AID-CNCR2820510716>3.0.CO;2-U","article-title":"Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone","volume":"51","author":"Murphy","year":"1983","journal-title":"Cancer"},{"issue":"15","key":"10.1002\/14651858.CD013245.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013245.pub2-BIB0060|cit60","first-page":"81","article-title":"Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer","volume":"32 Suppl 3","author":"Pummer","year":"1997","journal-title":"European Urology"},{"issue":"2","key":"10.1002\/14651858.CD013245.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"63","DOI":"10.14740\/wjon1191","article-title":"Epidemiology of Prostate Cancer","volume":"10","author":"Rawla","year":"2019","journal-title":"World J Oncol"},{"key":"10.1002\/14651858.CD013245.pub2-BIB0062|cit62","unstructured":"Review Manager 5 (RevMan 5) Nordic Cochrane Centre, The Cochrane Collaboration 2014"},{"issue":"2","key":"10.1002\/14651858.CD013245.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD013245.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","article-title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","volume":"16","author":"Ryan","year":"2015","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD013245.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejca.2017.07.003","article-title":"Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: a\u00a0systematic review and meta-analysis","volume":"84","author":"Rydzewska","year":"2017","journal-title":"European Journal of Cancer"},{"issue":"9","key":"10.1002\/14651858.CD013245.pub2-BIB0066|cit66","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012816","article-title":"Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer","author":"Sathianathen","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD013245.pub2-BIB0067|cit67","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012816.pub2","article-title":"Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer","author":"Sathianathen","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD013245.pub2-BIB0068|cit68","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.eururo.2019.09.004","article-title":"Indirect comparisons of efficacy between combination approaches in metastatic hormone-sensitive prostate cancer: a systematic review and network meta-analysis","volume":"77","author":"Sathianathen","year":"2019","journal-title":"European Urology"},{"issue":"6","key":"10.1002\/14651858.CD013245.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.euo.2019.01.004","article-title":"A cost-effectiveness analysis of systemic therapy for metastatic hormone-sensitive prostate cancer","volume":"2","author":"Sathianathen","year":"2019","journal-title":"European Urology Oncology"},{"issue":"7","key":"10.1002\/14651858.CD013245.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"13","key":"10.1002\/14651858.CD013245.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013245.pub2-BIB0072|cit72","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JP Vist GE Glasziou P Guyatt GH Chapter 11: Presenting results and \u2018Summary of findings' tables. In: Higgins JP, Green S, editor(s), Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/cochrane-handbook"},{"issue":"1","key":"10.1002\/14651858.CD013245.pub2-BIB0073|cit73","first-page":"7","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA: a Cancer Journal for Clinicians"},{"issue":"6","key":"10.1002\/14651858.CD013245.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1074\/jbc.M111.261933","article-title":"Direct regulation of androgen receptor activity by potent CYP17 inhibitors in prostate cancer cells","volume":"287","author":"Soifer","year":"2012","journal-title":"Journal of Biological Chemistry"},{"issue":"8","key":"10.1002\/14651858.CD013245.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"15","key":"10.1002\/14651858.CD013245.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD013245.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.euf.2016.11.013","article-title":"Understanding mechanisms of resistance in metastatic castration-resistant prostate cancer: the role of the androgen receptor","volume":"2","author":"Tilki","year":"2016","journal-title":"European Urology Focus"},{"issue":"2","key":"10.1002\/14651858.CD013245.pub2-BIB0078|cit78","first-page":"87","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA: a Cancer Journal for Clinicians"},{"issue":"5","key":"10.1002\/14651858.CD013245.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1093\/annonc\/mdy071","article-title":"What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis","volume":"29","author":"Vale","year":"2018","journal-title":"Annals of Oncology"},{"issue":"6","key":"10.1002\/14651858.CD013245.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.eururo.2017.10.002","article-title":"Comparison of abiraterone acetate and docetaxel with androgen deprivation therapy in high-risk and metastatic hormone-naive prostate cancer: a systematic review and network meta-analysis","volume":"73","author":"Wallis","year":"2018","journal-title":"European Urology"},{"issue":"9","key":"10.1002\/14651858.CD013245.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1200\/JCO.2009.22.2265","article-title":"Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix","volume":"28","author":"Zelefsky","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD013245.pub2-BIB0082|cit82","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013245","article-title":"Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer","author":"Sathianathen","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T00:07:38Z","timestamp":1710979658000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD013245.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Urology Group","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2020,12,12]]},"references-count":82,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,12]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd013245.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,12]]}}}